Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.1998
Nov 16 • 3:59 PM ET Dollar change-0.0302 Percentage change(-13.13%)
Aftermarket Close
0.2044
Aftermarket • 7:50 PM ET Dollar change+0.0046 Percentage change(2.30%)
Today, 4:55 PMVolitionRx expanded its Fujifilm Japan supply agreement to include development and use of its Nu.Q Vet feline cancer test.
Index
-
Market Cap
7.21M
Enterprise Value
11.61M
Income
-24.62M
Sales
3.44M
Book/sh
-0.80
Cash/sh
0.07
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
75
IPO
Apr 25, 2007
P/E
-
Forward P/E
-
PEG
-
P/S
2.10
P/B
-
P/C
3.06
P/FCF
-
EV/EBITDA
-
EV/Sales
3.38
Quick Ratio
0.33
Current Ratio
0.33
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-3.05
EPS next Y
-0.73
EPS next Q
-0.25
EPS this Y
55.97%
EPS next Y
62.15%
EPS next 5Y
57.20%
EPS past 3/5Y
26.33% 13.42%
Sales past 3/5Y
77.98% 164.15%
EPS Y/Y TTM
32.90%
Sales Y/Y TTM
134.01%
EPS Q/Q
79.23%
Sales Q/Q
157.28%
Insider Own
4.77%
Insider Trans
0.00%
Inst Own
7.85%
Inst Trans
1.25%
ROA
-360.73%
ROE
-
ROIC
-
Gross Margin
67.89%
Oper. Margin
-512.60%
Profit Margin
-714.86%
SMA20
4.76%
SMA50
-11.73%
SMA200
-89.30%
Trades
Shs Outstand
32.81M
Shs Float
26.57M
52W High
7.73 -97.41%
52W Low
0.16 27.75%
Volatility
17.23% 11.78%
ATR (14)
0.03
RSI (14)
47.33
Beta
1.14
Rel Volume
0.50
Avg Volume
9.31M
Volume
4,645,917
Perf Week
-0.10%
Perf Month
10.94%
Perf Quarter
-57.86%
Perf Half Y
-91.24%
Perf YTD
-96.09%
Perf Year
-96.98%
Perf 3Y
-98.69%
Perf 5Y
-99.75%
Perf 10Y
-99.76%
Prev Close
0.23
Price
0.20
Change %
-13.13%
Consensus
Buy
Avg. Price Target
$8.04
Implied Upside
+3,924.0%
Analysts5incl. previous ratings
Rating Distribution4 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 08, 2025Initiated
HH.C. Wainwright
Buy$2.50+1,151.3%
Feb 01, 2023Downgrade
TThe Benchmark Company
Buy → Hold
Feb 17, 2022Resumed
CCantor Fitzgerald
Overweight$8 → $7+3,403.5%
Mar 10, 2021Initiated
CCantor Fitzgerald
Overweight$8+3,904.0%
May 16, 2018Initiated
MMaxim Group
Buy$6+2,903.0%
May 14, 2018Reiterated
TThe Benchmark Company
Buy$7 → $5+2,402.5%
Sep 07, 2016Reiterated
RRodman & Renshaw
Buy$12 → $10+4,905.0%
Feb 01, 2016Initiated
RRodman & Renshaw
Buy$12+5,906.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reynolds Cameron JohnPresident and CEONov 17 '25Buy0.3520,0007,0002,554,847Nov 17 01:12 PM
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
FounderMr. Cameron Reynolds MBA
Chief Operating OfficerDr. Gaetan Michel Ph.D.
CFO & TreasurerMr. Terig Hughes
Ph.D.Dr. Jacob Vincent Micallef MBA
Group General CounselMr. Nicholas Plummer